Latest Earnings Results: Q3 '26
Estimated EPS
-$0.85
Reported EPS
-$0.28
Surprise
+67.06%
Estimated Rev
$1.38M
Reported Rev
---
Surprise
---
Precision BioSciences reported Q3 2026 revenue of $0, total operating expenses of $20.43M, operating loss of $20.43M, and net loss of $7.59M, versus $21.77M net loss in Q3 2025.
Bullish Takeaway
Precision BioSciences expanded ELIMINATE-B cohorts, dosed the first FUNCTION-DMD patient, and reported partner-program outcomes: reduced hyperammonemic events and crises, and stable or improved disability scores at Day 90.
Bearish Takeaway
Precision BioSciences reported no Q3 revenue and continuing losses, needs additional capital that may dilute stockholders, and warns other technologies may provide significant advantages over ARCUS while early trial results may not predict later outcomes.
Generated by Stocktwits using AI and company-reported earnings data for Q3 '26. This recap is intended to help readers understand the quarter quickly. Verify key figures in the linked source materials; the summary may contain errors and is not investment advice.
Historical Earnings
Quarterly
Annual
EPS
Revenue
| Fiscal Period | Estimated | Reported | Surprise | Result |
|---|---|---|---|---|
Q4 '26 | -$0.74 | -- | -- | N/A |
Q3 '26 | -$0.85 | -$0.28 | 67.06% | BEAT |
Q2 '26 | -$0.80 | -$1.26 | -56.72% | MISSED |
Q1 '26 | -$0.65 | -$0.75 | -14.50% | MISSED |
Q4 '25 | -$0.54 | $1.05 | 296.26% | BEAT |